Skip to main content
main-content

Video commentaries


Expert commentaries from clinicians and researchers on clinical trials, guidelines and topical issues in diabetes care.


13-06-2019 | Prediabetes | ADA 2019 | Article

Expert commentary: The RISE study

With all three RISE studies now published, John Wilding reflects on the pathophysiological differences between children and adults with type 2 diabetes (2:12).

13-06-2019 | Physical activity | ADA 2019 | Article

Expert highlights: High performance exercise and type 1 diabetes

John Wilding talks about research presented at the ADA Scientific Sessions looking at the management of type 1 diabetes in elite athletes (3:18).

13-06-2019 | Insulin degludec/Liraglutide | ADA 2019 | Article

Expert commentary: The DUAL VIII trial

Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).

12-06-2019 | Linagliptin | ADA 2019 | Article

Expert commentary: An endocrinologist's view of the CAROLINA trial

Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).

12-06-2019 | Linagliptin | ADA 2019 | Article

Clinical takeaway: The CAROLINA trial

John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

11-06-2019 | Semaglutide | ADA 2019 | Article

Researcher comment: The PIONEER 6 oral semaglutide cardiovascular outcomes study

PIONEER 6 lead investigator Mansoor Husain discusses the results of the trial, and how oral and injectable semaglutide compare and can be used in the clinic (4:40).

10-06-2019 | ADA 2019 | Article

Expert highlights: ADA session “Making a difference in 5 minutes”

Lori Berard gives an overview of the ADA session “Making a difference in five minutes: Interventions in diabetes for anyone.” (2:0)

10-06-2019 | Hypoglycemia | ADA 2019 | Article

Expert highlights: Novel insulins and insights into hypoglycemia from continuous glucose monitoring

Stephanie Amiel overviews her ADA highlights, including novel rapid-acting insulins and the sometimes surprising insights that technology offers into hypoglycemia (3:20).

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: A nurse educator’s view of the REWIND trial

Nurse educator Lori Berard gives her view of how the REWIND trial can help clinicians working with people with type 2 diabetes (1:48).

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: The REWIND trial

John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: A primary care view of the REWIND trial

Kamlesh Khunti discusses what the REWIND findings mean for doctors working with people with type 2 diabetes and high cardiovascular risk in primary care (1:43).

07-06-2019 | Prediabetes | ADA 2019 | Article

Expert commentary: The D2d trial

Kim Pfotenhauer considers whether the D2d trial has settled the question of the role of vitamin D in the prevention of type 2 diabetes (1:53).

16-04-2019 | Nephropathy | Video | Article

Diabetes expert commentary: The CREDENCE trial

In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).

08-03-2019 | Psychosocial care | Video | Article

Patient engagement skills and eating disorders

Psychological Wellbeing Practitioner Abeni Lüken outlines the patient engagement techniques that healthcare practitioners can use to facilitate open and positive discussions about eating disorders (4:08).

07-03-2019 | Diet | Video | Article

Researcher comment: The 2-year outcomes of the DiRECT trial

Roy Taylor explains why the DiRECT intervention may benefit a surprisingly wide variety of people, and how the trial’s findings could trigger a major shift in thinking about how to tackle type 2 diabetes (6:45).

Image Credits